Journal
Clinical Cancer Research
Publication Date
4-1-2025
Volume
31
Issue
7
First Page
1257
Last Page
1267
Document Type
Open Access Publication
DOI
10.1158/1078-0432.CCR-24-1991
Rights and Permissions
El-Khoueiry A, Saavedra O, Thomas J, Livings C, Garralda E, Hintzen G, Kohlhas L, Vanosmael D, Koch J, Rajkovic E, Ravenstijn P, Nuciforo P, Fehniger TA, Foster M, Berrien-Elliott MM, Wingert S, Stäble S, Morales-Espinosa D, Rivas D, Emig M, Lopez J. First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors. Clin Cancer Res. 2025 Apr 1;31(7):1257-1267. doi: 10.1158/1078-0432.CCR-24-1991 ©2025 The Authors; Published by the American Association for Cancer Research This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
Recommended Citation
El-Khoueiry, Anthony; Fehniger, Todd A; Foster, Mark; Berrien-Elliott, Melissa M; and et al., "First-in-human phase I study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-expressing solid tumors." Clinical Cancer Research. 31, 7. 1257 - 1267. (2025).
https://digitalcommons.wustl.edu/oa_4/4937
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
